代谢组学在新精神活性物质研究中的应用

doi:10.3969/j.issn.1671-2072.2025.02.004

摘要/Abstract

摘要： 新精神活性物质（new psychoactive substances，NPS）种类繁多，更迭迅速，鉴别检测困难，风险评估与法律监管滞后，现已成为公共卫生健康与社会稳定的一大威胁。代谢组学是研究系统生物学的有力工具，通过对代谢物进行定性、定量分析，反映生物系统内发生的多种生化过程。总结近年来代谢组学在NPS研究中的应用进展：利用代谢组学与其他研究方法相结合，可探索NPS治疗帕金森病、抑郁症等神经系统功能障碍的药理作用机制，考察NPS成瘾机制，研究不同种类NPS的毒性反应及机制。通过这些研究，可以预测NPS的药理活性，为多种神经系统疾病寻找潜在的治疗药物，预防或减轻成瘾、缓解或治疗毒性反应，以及为NPS的深入研究提供新见解。尽管目前代谢组学在NPS中的研究有限，但其应用前景广阔，有待进一步探索。

关键词: 新精神活性物质（NPS）, 代谢组学, 药理作用, 成瘾机制, 毒性作用机制

Abstract: New psychoactive substances (NPS) pose a significant threat to public health and social stability due to their wide variety, rapid turnover, difficulty in identification and detection, and lagging risk assessment and legal regulation. Metabolomics is a powerful tool for studying systems biology, reflecting the biochemical processes occurring in biological systems through the qualitative and quantitative analysis of metabolites. This review summarises recent progress in the application of metabolomics in NPS research. By combining metabolomics with other research methods, we can explore the pharmacological mechanisms of NPS for treating Parkinson’s disease, depression, and other neurological dysfunctions. We can also examine the mechanisms of NPS addiction, the toxic responses and mechanisms of different types of NPS. These studies can predict the psychopharmacological activity of NPS, identify potential therapeutic agents for neurological disorders, prevent or alleviate addiction, treat toxic reactions, and provide insights for further research on NPS. Although metabolomics in NPS is currently limited, its potential application is promising and requires further exploration.

Key words: new psychoactive substance（NPS）, metabolomics, pharmacological function, addiction mechanism, toxicity mechanicm

中图分类号:

DF795.1

钱小雨, 向平, 严慧. 代谢组学在新精神活性物质研究中的应用[J]. 中国司法鉴定, 2025(2): 31-39.

QIAN Xiaoyu, XIANG Ping, YAN Hui. Application of Metabolomics in the Investigation of New Psychoactive Substances[J]. Chinese Journal of Forensic Sciences, 2025(2): 31-39.

参考文献

[ 1 ] United Nations Office on Drugs and Crime. Early Warning Advisory （EWA） on New Psychoactive Substances （NPS）[EB/OL]. [2024-01-24]. https：//www.unodc.org/LSS/Home/NPS.
[ 2 ] CHIAPPINI S，MOSCA A，MIULI A，et al. New psychoactive substances and suicidality：A systematic review of the current literature[J]. Medicina，2021，57（6）：580.
[ 3 ] ZAPATA F，MATEY J M，MONTALVO G，et al. Chemical classification of new psychoactive substances （NPS）[J]. Microchemical Journal，2021，163：105877.
[ 4 ] GIORGETTI A，PASCALI J P，FAIS P，et al. Molecular mechanisms of action of novel psychoactive substances （NPS）. A new threat for young drug users with forensic-toxicological implications[J]. Life，2021，11（5）：440.
[ 5 ] KLINGBERG J，KEEN B，CAWLEY A，et al. Developments in high-resolution mass spectrometric analyses of new psychoactive substances[J]. Archives of Toxicology，2022，96（4）：949-967.
[ 6 ] SZEREMETA M，PIETROWSKA K，NIEMCUNOWICZ-JANICA A，et al. Applications of metabolomics in forensic toxicology and forensic medicine[J]. International Journal of Molecular Sciences，2021，22（6）：3010.
[ 7 ] STEUER A E，BROCKBALS L，KRAEMER T. Metabolomic strategies in biomarker research-new approach for indirect identification of drug consumption and sample manipulation in clinical and forensic toxicology?[J]. Frontiers in Chemistry，2019，7：319.
[ 8 ] ZEKI Ö C，EYLEM C C，REÇBER T，et al. Integration of GC-MS and LC-MS for untargeted metabolomics profiling[J]. Journal of Pharmaceutical and Biomedical Analysis，2020，190：113509.
[ 9 ] FU S L，STOVE C，ELLIOTT S. Editorial：Advances in analytical methods for drugs of abuse testing[J]. Frontiers in Chemistry，2019，7：589.
[10] ZAITSU K，HAYASHI Y，KUSANO M，et al.Application of metabolomics to toxicology of drugs of abuse：A mini review of metabolomics approach to acute and chronic toxicity studies[J]. Drug Metabolism and Pharmacokinetics，2016，31（1）：21-26.
[11] SAIGUSA D，MATSUKAWA N，HISHINUMA E，et al. Identification of biomarkers to diagnose diseases and find adverse drug reactions by metabolomics[J]. Drug Metabolism and Pharmacokinetics，2021，37：100373.
[12] 杜铁帅，孟西麦蒙，叶星，等. 代谢组学技术在法医病理学中的研究进展[J]. 法医学杂志，2020，36（3）：347-353.
[13] DAWIDOWSKA J，KRZYŻANOWSKA M，MARKUSZEWSKI M J，et al. The application of metabolomics in forensic science with focus on forensic toxicology and time-of-death estimation[J]. Metabolites，2021，11（12）：801.
[14] CASTILLO-PEINADO L S，LUQUE DE CASTRO M D. Present and foreseeable future of metabolomics in forensic analysis[J]. Analytica Chimica Acta，2016，925：1-15.
[15] 严秀莺，向平. 代谢组学在滥用物质毒理学研究中的应用[J]. 法医学杂志，2022，38（3）：400-407.
[16] KADDURAH-DAOUK R，KRISTAL B S，WEINSHILBOUM R M. Metabolomics：A global biochemical approach to drug response and disease[J]. Annual Review of Pharmacology and Toxicology，2008，48：653-683.
[17] STEUER A E，KAELIN D，BOXLER M I，et al. Comparative untargeted metabolomics analysis of the psychostimulants 3，4-methylenedioxy-methamphetamine （MDMA），amphetamine，and the novel psychoactive substance mephedrone after controlled drug administration to humans[J]. Metabolites，2020，10（8）：306.
[18] KATCHBORIAN-NETO A，SANTOS W T，NICÁCIO K J，et al.Neuroprotective potential of Ayahuasca and untargeted metabolomics analyses：Applicability to Parkinson’s disease[J]. Journal of Ethnopharmacology，2020，255：112743.
[19] ZANDONADI F S，SILVA A R，MELO A A S，et al. Understanding ayahuasca effects in major depressive disorder treatment through in vitro metabolomics and bioinformatics[J]. Analytical and Bioanalytical Chemistry，2023，415（18）：4367-4384.
[20] KADRIU B，YUAN P X，MOADDEL R，et al.S93.Ketamine treatment modulates the kynurenine and arginine pathways in depressed unipolar and bipolar patients[J]. Biological Psychiatry，2019，85（10）：S333.
[21] SINGH B，MAHMOUDIANDEHKORDI S，VOORT J L V，et al. Metabolomic signatures of intravenous racemic ketamine associated remission in treatment-resistant depression：A pilot hypothesis generating study[J]. Psychiatry Research，2022，314：114655.
[22] ALQAHTANI F，ASSIRI M A，MOHANY M，et al. Coadministration of ketamine and perampanel improves behavioral function and reduces inflammation in acute traumatic brain injury mouse model[J]. BioMed Research International，2020，2020：3193725.
[23] WHELAN J，FRITSCHE K. Linoleic acid[J]. Advances in Nutrition，2013，4（3）：311-312.
[24] ZHENG F，XIA Z A，ZENG Y F，et al. Plasma metabolomics profiles in rats with acute traumatic brain injury[J]. PLOS One，2017，12（8）：e0182025.
[25] OLESTI E，DE TOMA I，RAMAEKERS J G，et al. Metabolomics predicts the pharmacological profile of new psychoactive substances[J]. Journal of Psychopharmacology，2019，33（3）：347-354.
[26] OLESTI E，RODRíGUEZ-MORATÓ J，GOMEZ-GOMEZ A，et al. Quantification of endogenous neurotransmitters and related compounds by liquid chromatography coupled to tandem mass spectrometry[J]. Talanta，2019，192：93-102.
[27] BAUMANN M H，PARTILLA J S，LEHNER K R，et al. Powerful cocaine-like actions of 3，4-methylenedioxypyrovalerone （MDPV），a principal constituent of psychoactive “bath salts” products[J]. Neuropsychopharmacology，2013，38（4）：552-562.
[28] YUE B F，PATTISON E，ROBERTS W L，et al. Choline in whole blood and plasma：Sample preparation and stability[J]. Clinical Chemistry，2008，54（3）：590-593.
[29] VIANA R R，PEGO A M F，DE OLIVEIRA T F，et al. Liquid chromatography-tandem mass spectrometry method for simultaneous quantification of neurotransmitters in rat brain tissue exposed to 4′‐fluoro‐α‐PHP[J]. Biomedical Chromatography，2022，36（12）：e5487.
[30] MARUSICH J A，GAY E A，BLOUGH B E. Analysis of neurotransmitter levels in addiction-related brain regions during synthetic cathinone self-administration in male Sprague-Dawley rats[J]. Psychopharmacology，2019，236（3）：903-914.
[31] KOOB G F，VOLKOW N D. Neurocircuitry of addiction[J]. Neuropsychopharmacology，2010，35（1）：217-238.
[32] ZHAO S，LIU M，CHEN J Y，et al. Pathophysiological impacts of 5-MeO-MiPT on zebrafish （Danio rerio） via the Gαq/11-PLCβ signaling pathway[J]. Ecotoxicology and Environmental Safety，2024，283：116969.
[33] ZHAO S，CHEN J Y，ZHONG C H，et al. Nontargeted metabolomic insights into the behavioral effects of 5-MeO-MiPT in zebrafish （Danio rerio）[J]. Ecotoxicology and Environmental Safety，2024，272：116044.
[34] 周漪颖，崔巍，张鑫，等. 新精神活性物质分类现状与管制展望[J]. 中国药物滥用防治杂志，2020，26（6）：311-317.
[35] MARKIN P A，BRITO A，MOSKALEVA N E，et al. Short and long-term exposures of the synthetic cannabinoid 5F-APINAC induce metabolomic alterations associated with neurotransmitter systems and embryotoxicity confirmed by teratogenicity in zebrafish[J]. Comparative Biochemistry and Physiology Part C：Toxicology & Pharmacology，2021，243：109000.
[36] SHESTAKOVA K M，MESONZHNIK N V，MARKIN P A，et al. Pharmacokinetic properties of the novel synthetic cannabinoid 5F-APINAC and its influence on metabolites associated with neurotransmission in rabbit plasma[J]. Pharmaceuticals，2021，14（7）：668.
[37] ZAITSU K，HAYASHI Y，SUZUKI K，et al.Metabolome disruption of the rat cerebrum induced by the acute toxic effects of the synthetic cannabinoid MAM-2201[J]. Life Sciences，2015，137：49-55.
[38] LI R S，FUKUMORI R，TAKEDA T，et al. Elevation of endocannabinoids in the brain by synthetic cannabinoid JWH-018：Mechanism and effect on learning and memory[J]. Scientific Reports，2019，9（1）：9621.
[39] ZUL AZNAL A N，MOHAMAD NOR HAZALIN N A，HASSAN Z，et al. Adolescent kratom exposure affects cognitive behaviours and brain metabolite profiles in Sprague-Dawley rats[J]. Frontiers in Pharmacology，2022，13：1057423.
[40] SUHAIMI F W，ZUL AZNAL A N，MOHAMAD NOR HAZALIN N A，et al. Kratom （M. speciosa） exposure during adolescence caused long-lasting cognitive behavioural deficits associated with perturbated brain metabolism pathways in adult rats[J]. Behavioural Brain Research，2023，446：114411.
[41] ARAÚJO A M，CARVALHO M，BASTOS M D L，et al. Metabolic signature of methylone in primary mouse hepatocytes，at subtoxic concentrations[J]. Archives of Toxicology，2019，93（11）：3277-3290.
[42] ARAÚJO A M，BASTOS M L，CARVALHO F，et al. Effect of temperature on 3，4-Methylenedioxypyrovalerone （MDPV）-induced metabolome disruption in primary mouse hepatic cells[J]. Toxicology，2020，441：152503.
[43] ARAÚJO A M，CARVALHO M，COSTA V M，et al. In vivo toxicometabolomics reveals multi-organ and urine metabolic changes in mice upon acute exposure to human-relevant doses of 3，4-methylenedioxypyrovalerone （MDPV）[J]. Archives of Toxicology，2021，95（2）：509-527.
[44] MANIER S K，WAGMANN L，FLOCKERZI V，et al. Toxicometabolomics of the new psychoactive substances α-PBP and α-PEP studied in HepaRG cell incubates by means of untargeted metabolomics revealed unexpected amino acid adducts[J]. Archives of Toxicology，2020，94（6）：2047-2059.
[45] WANG Y，YANG Y，ZHAN Y J，et al. Pharmacokinetics and metabolomics of the new psychoactive substance 4-chloroethylcathinone[J]. Arabian Journal of Chemistry，2023，16（9）：105039.
[46] CHEN F，YE Y，DAI X H，et al.Metabolic effects of repeated ketamine administration in the rat brain[J]. Biochemical and Biophysical Research Communications，2020，522（3）：592-598.
[47] WEI Y，XIAO L，FAN W H，et al. Comprehensive metabolomic characterization of the hippocampus in a ketamine mouse model of schizophrenia[J]. Biochemical and Biophysical Research Communications，2022，632：150-157.
[48] DHUMMAKUPT E S，RIZZO G M，FEASEL M，et al. Proteomic and metabolomic profiling identify plasma biomarkers for exposure to ultra-low levels of carfentanil[J]. Toxicological Sciences，2019，167（2）：524-535.
[49] ALASMARI F，ALASMARI M S，ASSIRI M A，et al. Liver metabolomics and inflammatory profiles in mouse model of fentanyl overdose treated with beta-lactams[J]. Metabolites，2023，13（8）：965.
[50] DI FRANCESCO G，MONTESANO C，VINCENTI F，et al. Tackling new psychoactive substances through metabolomics：UHPLC-HRMS study on natural and synthetic opioids in male and female murine models[J]. Scientific Reports，2024，14（1）：9432.
[51] ALSEEKH S，AHARONI A，BROTMAN Y，et al. Mass spectrometry-based metabolomics：A guide for annotation，quantification and best reporting practices[J]. Nature Methods，2021，18（7）：747-756.
[52] GONZALEZ-COVARRUBIAS V，MARTÍNEZ-MARTíNEZ E，DEL BOSQUE-PLATA L. The potential of metabolomics in biomedical applications[J]. Metabolites，2022，12（2）：194.
[53] VOLKOW N D，KOOB G，BALER R. Biomarkers in substance use disorders[J]. ACS Chemical Neuroscience，2015，6（4）：522-525.